Supplementary data:
Maximal testosterone suppression in the management of recurrent and metastatic prostate cancer
Can Urol Assoc J
.
2017 Jan-Feb;11(1-2):E62-E63.
doi: 10.5489/cuaj.4494.
Epub 2017 Feb 20.
Authors
Laurence Klotz
1
,
Rodney H Breau
2
,
Loretta L Collins
3
,
Martin E Gleave
4
,
Tom Pickles
5
,
Frederic Pouliot
6
,
Fred Saad
7
Affiliations
1
Sunnybrook Health Sciences Centre, Toronto, ON, Canada.
2
Ottawa Hospital Research Institute, Ottawa, ON, Canada.
3
Kaleidoscope Strategic, Toronto, ON, Canada.
4
Vancouver Prostate Centre, Vancouver, BC, Canada.
5
British Colombia Cancer Agency, Vancouver, BC, Canada.
6
Hôtel-Dieu de Québec, Quebec City, QC, Canada.
7
Centre Hospitalier de l'Université de Montréal, Montreal, QC, Canada.
PMID:
28443152
PMCID:
PMC5403685
DOI:
10.5489/cuaj.4494
No abstract available
Publication types
Review